| Literature DB >> 35629364 |
Ayyanar Sivanantham1, Yang Jin1.
Abstract
Extracellular vesicles (EVs) are small biological particles released into biofluids by every cell. Based on their size, they are classified into small EVs (<100 nm or <200 nm) and medium or large EVs (>200 nm). In recent years, EVs have garnered interest for their potential medical applications, including disease diagnosis, cell-based biotherapies, targeted drug delivery systems, and others. Currently, the long-term and short-term storage temperatures for biofluids and EVs are -80 °C and 4 °C, respectively. The storage capacity of EVs can depend on their number, size, function, temperature, duration, and freeze-thaw cycles. While these parameters are increasingly studied, the effects of preservation and storage conditions of EVs on their integrity remain to be understood. Knowledge gaps in these areas may ultimately impede the widespread applicability of EVs. Therefore, this review summarizes the current knowledge on the effect of storage conditions on EVs and their stability and critically explores prospective ways for improving long-term storage conditions to ensure EV stability.Entities:
Keywords: biotherapeutics; extracellular vesicles (EVs); freeze-thaw cycle; long-term storage; stability; temperature
Year: 2022 PMID: 35629364 PMCID: PMC9146501 DOI: 10.3390/life12050697
Source DB: PubMed Journal: Life (Basel) ISSN: 2075-1729
Figure 1Biogenesis of EVs and their components. Medium EVs (mEVs) or large EVs (lEVs) are produced when the plasma membrane begins to bud. mEVs/lEVs are (>200 nm), irregular in shape, and may include cytoplasmic components. Surface markers such as integrins, CD40, selectins, and proteins from the cell are present. Small EVs (sEVs) are derived from the endosomal trafficking pathway and so have a more consistent shape and size (<200). sEVs are more readily identified than mEVs/lEVs by cell surface markers such as CD9, CD63, and CD81, and may include mitochondrial DNA, messenger RNA, and microRNA. MVB: multi-vesicular bodies; CD: cluster of differentiation. This figure was created with BioRender.com, accessed on 29 March 2022.
EV types, surface markers, and cargos.
| Features | Apoptotic Bodies | MVs | Exosomes |
|---|---|---|---|
| Shape | Heterogeneous | Heterogeneous | Spherical |
| Size (nm) | 50–5000 | 100–1000 | 30–150 |
| Formation mechanism | Nuclear chromatin condensation, followed by membrane blebbing | Plasma membrane direct outward budding and fission | Endosomal network fusion with the plasma membrane |
| Release or response | Apoptosis | Cell injury, proinflammatory stimulants, hypoxia, oxidative stress or shear stress | Cellular stress or activation signals |
| Surface markers | Apoptotic cell markers | Selectins, integrin, CD40, CD31+, CD235a+, CD42b−, CD45, CD61+, CD62E+, and CD144+, | Tetraspanins (CD9, CD63 CD81 and CD82) |
| Cargos and other markers | Intact chromatin, glycosylated proteins, Caspase 3, histones, HSP60, and GRP78 | Cytoskeletal proteins, heat shock proteins, integrins, and proteins containing post-translational modifications, such as glycosylation and phosphorylation | ALIX, TSG-101, PODXL, HSP70, and HSP90β |
Summary of the impact of storage conditions on EV-containing biofluids.
| Source | Type of EVs | Storage Temperature/pH/Cryopreserves | Duration | Freeze-Thaw Cycles | Physical Changes | Functional Changes | References |
|---|---|---|---|---|---|---|---|
|
| EV | −80 °C | 4 days | - | Disruption in the surface and morphological characteristics and ↓ total protein content | - | [ |
|
| MP | −80 °C | 1 week and 1 year | 1 | Microparticle counts are stable | - | [ |
| EV | RT | 24 h | - | - | ↓ miR-21 and miR-142-3p | [ | |
| EV | 4 and −70 °C | 96 h and 28 days | - | - | miR-21, miR-200b, and miR-205 expression was stable | [ | |
|
| exosomes | RT, 4 °C, | Days and Months | - | - | The stable expression in signals under storage at RT and 4 °C for long-term storage. | [ |
|
| Microparticles | 4 °C and −80 °C | 7 h, 7 and 28 days | - | ↑ expression of CD31+, CD42b- and CD62E+ | - | [ |
| EV | −80 °C | 10–12 days | - | ↓ EV concentration | - | [ | |
| EV | −80 °C | 6 months | - | ↓ Particle concentration | - | [ | |
| EV | −80 °C | 12 months | 1 | - | ↓ level of AnnV+ before thaw; and ↑ level of AnnV+ after a single freeze-thaw cycle | [ | |
| Exosomes | RT | 0–48 h | - | - | Ct value of exosomal let-7a and miR-142-3p were stable | [ | |
| −80 °C | 7 years | - | - | ↑ Amount of total protein and protein/nucleic acid aggregation | [ | ||
|
| MV | −80 °C | 24 h | - | ↑ MV secretion | - | [ |
| EV | pathogen reduction technology (PRT) treatment with Mirasol® (vitamin B2plus UVB light) | 2 and 7 days | - | ↑151 proteins, including EV markers | [ | ||
| EVs | Frozen with 6% DMSO | - | ↑ EV production | Procoagulant activity was stable | [ | ||
|
| EV | 4 °C | 50 days | - | ↑ 20-folds Particle counts | - | [ |
|
| EV | 4 °C and | 2–8 weeks | - | - | No changes in CD63 and CD9 expression | [ |
| Exosomes | −80 °C | 4 week | - | ↑ contamination by stress-induced exosomes | - | [ | |
| 6 month | - | [ | |||||
| EV | 4 °C | 24 h | - | - | ↓ 2-fold-miR-21 expression | [ | |
|
| Exosomes | −20 °C & | 1 week | - | ↓ EV associated | - | [ |
| 4 °C and −80 °C | 24 h | - | Stable expression of TSG101, AQP2, angiotensin-converting enzyme, and PODXL | - | [ | ||
| RT, 4 °C and −80 °C | 2 h–7 days | - | ↓ EV yield | - | [ | ||
|
| Exosomes | −80 °C | 2 and 30 years | - | Size, structure, or concentration are stable | ↓ Amount of protein, AChE, and anti-HIV activities on long-term freezing. But total RNA level is stable | [ |
|
| EV | −80 °C | 1 year | 1 | ↓ 2-fold EV concentration, | - | [ |
| Exosomes | 4 °C | 7 days | - | No changes in total protein, dipeptidyl peptidase IV activity, morphology, and surface markers (CD9, ALIX, and TSG101) | Degradation in some functional proteins | [ | |
|
| EVs | pH 5, 6 and 7 (cell culture condition) | 24 h | pH 5 cell culture condition increases its protein content and zeta potential. | ↑ EV uptake into recipient cells | [ | |
|
| EV | RT, 4 °C, −20 °C and −80 °C | 10 days | - | ↓ CD63 expression under storage at RT and 4 °C. | Exosome uptake efficiency and biodistribution were significantly decreased when stored at 4 °C and −20 °C | [ |
| Exosomes | 60 °C, 37 °C, 4 °C, −20 °C, and −80 °C at pH 4, 7, or 10 | 1 day | 2 | No changes occur in ALIX, HSP70, and TSG101 at 4 °C. | ↑ Cellular uptake of exosomes at pH4 and 10. | [ | |
|
| EV | 37.4, −20, and −70 °C | 25 days | - | ↓ particle number and ↑ size on 37.4, and −20 °C | ↓ CD-63 and -81 expression under storage at 37 °C. | [ |
|
| EV | 4 °C and −80 °C | 1 week, 2 weeks, or 1 month | - | Stable EV concentration on all temperature | - | [ |
|
| Exosomes | 4 °C, −20 °C, and −80 °C | 0–28 days | 1–5 | ↓ particle number and ↑ size under all storage conditions. | ↓ Amount of protein, RNA, and uptake efficiency at 4 °C. | [ |
|
| EVs | Lyophilized and held at RT | 7 days | 2 | ↓37–43% in EV number. The shape of the EV is not stable | ↓ miRNAs abundance | [ |
↑—Increased; ↓—Decreased; A431 cells—Cellosaurus cell line; AchE—acetylcholine-esterase; ALIX—Apoptosis-linked gene 2–interacting protein X; AQP— Aquaporin 2; BALF—Bronchoalveolar lavage fluid; b. End.3—Brain endothelial-3 cells; CD—Cluster differentiation; CSF—cerebrospinal fluid; DNA—Deoxyribonucleic acid; EV—Extracellular vesicle; HEK293T—Human embryonic kidney 293 cells; HIV—Human immunodeficiency virus; HUVEC—Human umbilical vein endothelial cells; MP—Microparticle; miR—MicroRNA; MV— Microvesicle; PODXL—Podocalyxin-like protein; PI—Protease Inhibitor; RT—Room temperature; PRT—pathogen reduction technology; RBC—Red blood cells; RNA—Ribonucleic Acid; THP-1—human leukemia monocytic cell line; TSG—Tumor susceptibility gene and UVB—Ultraviolet B.
Summary of the impact of storage conditions on isolated EVs.
| Source | Type of EVs | Storage Temperature/pH/Cryopreserves | Duration | Freeze-Thaw Cycles | Physical Changes | Functional Changes | References |
|---|---|---|---|---|---|---|---|
|
| Exosomes | 4 °C, and −80 °C | 4 days | - | ↑ Size of exosome | ↓ protein concentration | [ |
|
| EV | 4 °C, −20 °C & −80 °C | 2 weeks–2 years | - | - | ↓ RNA or protein expression, storage at 4 °C for 2 weeks. | [ |
|
| EV | RT and 4 °C | 6 h–1 week | 1, 3, and 5 | - | No changes occur in CD63, TSG101, expression, and DNA concentration at RT storage for 24 h; and 4 °C for 1 week. | [ |
|
| EV | Lyophilization | 48 h | - | Particle size and zeta potential stable | - | [ |
|
| EV | −80 °C, 4 °C, RT, or lyophilized | 2–14 days | - | ↑ Particle size by −80 °C, 4 °C, RT | - | [ |
|
| EV | −80 °C, 4 °C, RT, or lyophilized | 2–14 days | - | ↓ Particle concentration and | - | |
|
| EV | −80 °C, 4 °C, RT, or lyophilized | 2–14 days | - | ↓ Particle concentration non-significantly after lyophilization | - | |
|
| EV | 4 °C, −80 °C and lyophilized with 4% trehalose | 14 days | - | ↑ size | ↓ Glucuronidase activity | [ |
|
| EV | lyophilized with trehalose or trehalose/PVP40 | 24 h | - | Particle number and size are stable | - | [ |
|
| EV | −80 °C | 6 months | 2 | ↓ Particle concentration | - | [ |
|
| EV | −80 °C with trehalose 25 mM, DMSO 6 and 10%, glycerol 30%, PI and sodium azide at 4 °C or lyophilization with trehalose | 6 months | - | stable EV concentrations | - | [ |
|
| EV | 4 °C | 24 h | - | No changes in physiological characteristics | No changes in functional characteristics | [ |
|
| Exosomes | pH < 7 at RT | 30 min | - | ↑Yield and ↓ Degradation | ↑ Exosome-associated doxorubicin at pH 5 | [ |
↑—Increased; ↓—Decreased; ALIX—Apoptosis-linked gene 2–interacting protein X; b.End.3 cells—Brain endothelial-3 cells; BALF—Bronchoalveolar lavage fluid; CD—Cluster differentiation; EV—Extracellular vesicle; HEK 293 cells—Human embryonic kidney 293 cells; HSP—Heat shock protein; HUVEC—Human umbilical vein endothelial cells; MSC—Mesenchymal stem cells; MV—Microvesicle; PI—Protease Inhibitor; RT—Room temperature; RNA—Ribonucleic Acid; and TSG—Tumor susceptibility gene.
Figure 2Impact of storage conditions on EVs. Various EV storage conditions and their potential effects on EV integrity. Biological sources or freshly isolated EVs are suspended in PBS with or without cryopreservants. Then, they are stored in specific conditions. The prolonged storage at low temperature induces mechanical damage, resulting in a loss in membrane integrity, leakage of EV cargo (RNA, protein, and lipids), and detachment of EV surface molecules (receptors and markers) due to the formation of tiny ice crystals within as well as around the EVs; Acidic or alkaline conditions reduce the number of EVs. Preservation methods also change the physiological properties of EVs and facilitate their product recovery. This figure was created with BioRender.com.